• Wion
  • /World
  • /FDA postpones meeting to discuss Pfizer's COVID vaccine for kids under 5

FDA postpones meeting to discuss Pfizer's COVID vaccine for kids under 5

FDA postpones meeting to discuss Pfizer's COVID vaccine for kids under 5

COVID vaccine

The U.S. Food and Drug Administration on Friday (February 11) said it was postponing an advisory panelmeetingthat was todiscussauthorization of Pfizer and BioNTech'sCOVID-19vaccinefor children 6 months through 4 years of age.

In a separate statement, the companies said they planned to extend the process of submitting data to U.S. regulators for the shot for childrenunder5.

U.S. regulators have been considering thevaccinefor the only age group not yet eligible for the shots, even though the companies said initial results fell short of expectations in 2- to 4-year olds.

Add WION as a Preferred Source

In December, Pfizer said it was amending its clinical trial to test a three-dose version of thevaccinebecause the low dose used generated an immune response inkidsaged 2 to 4 that was inferior to the response measured in those aged 16 to 25.

The companies had said they submitted data on the first two doses of what would eventually be a three-dose regimen in the age group at the request of theFDA. On Friday, they said they expect to have three-dose protection data available in early April.

Some scientists were critical of this idea, suggesting that regulators should wait for data from a third shot before deciding on authorization.

In very young children between 6 months and 2 years old, thevaccinegenerated an immune response in line with 16- to 25-year-olds, the companies had said.